Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Shares Outstanding (Weighted Average): 2015-2024

Historic Shares Outstanding (Weighted Average) for Seres Therapeutics (MCRB) over the last 10 years, with Dec 2024 value amounting to $8.5 million.

  • Seres Therapeutics' Shares Outstanding (Weighted Average) rose 15.40% to $8.8 million in Q3 2025 from the same period last year, while for Mar 2025 it was $8.7 million, marking a year-over-year increase of 15.46%. This contributed to the annual value of $8.5 million for FY2024, which is 32.09% up from last year.
  • Latest data reveals that Seres Therapeutics reported Shares Outstanding (Weighted Average) of $8.5 million as of FY2024, which was up 32.09% from $6.5 million recorded in FY2023.
  • Seres Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $8.5 million for FY2024, and its period low was $4.6 million during FY2020.
  • Over the past 3 years, Seres Therapeutics' median Shares Outstanding (Weighted Average) value was $6.5 million (recorded in 2023), while the average stood at $7.1 million.
  • Data for Seres Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY spiked of 35.65% (in 2022) over the last 5 years.
  • Yearly analysis of 5 years shows Seres Therapeutics' Shares Outstanding (Weighted Average) stood at $4.6 million in 2020, then rose by 0.66% to $4.6 million in 2021, then surged by 35.65% to $6.2 million in 2022, then increased by 3.74% to $6.5 million in 2023, then skyrocketed by 32.09% to $8.5 million in 2024.